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Background: Pulmonary hypertension is poorly studied in Africa. The long-term survival rates 
and prognostic factors associated with mortality in patients with moderate to severe pulmo-
nary hypertension (PH) in Africa are not well described. 
Objectives: To determine the causes of moderate to severe PH in patients seen in contemporary 
hospital settings, determine the patients’ one-year survival and the factors associated with 
mortality following standard care. 
Methods: A retrospective review of patients diagnosed with moderate to severe PH at Aga 
Khan University Hospital (AKUHN) from August 2014 to July 2017 was carried out. Clinical and 
outcome data were collected from medical records and the hospital mortality database. Tel-
ephone interviews were conducted for patients who died outside the hospital. Survival analysis 
was done using Kaplan-Meier, and log-rank tests were used to assess differences between sub-
groups. Cox regression modelling with multivariable adjustment was used to identify factors 
associated with all-cause mortality.
Results: A total of 659 patients with moderate to severe PH were enrolled. Median follow-up 
time was 626 days. The survival rates of the patients at 1 and 2 years were 73.8% and 65.9%, 
respectively. The following variables were significantly associated with mortality: diabetes 
mellitus [adjusted HR 1.52, 95% CI (1.14–2.01)], WHO functional class III/IV [adjusted HR 
3.49, 95% CI (2.46–4.95)], atrial fibrillation [adjusted HR 1.53, 95% CI (1.08–2.17)], severe 
PH [adjusted HR 1.72, 95% CI (1.30–2.27)], right ventricular dysfunction [adjusted HR 2.42, 
95% CI (1.76–3.32)] and left ventricular dysfunction [adjusted HR 1.91, 95% CI (1.36–2.69)]. 
Obesity [adjusted HR 0.68, 95% CI (0.50–0.93)] was associated with improved survival.
Conclusion: Pulmonary hypertension is associated with poor long-term outcomes in African 
patients. Identification of prognostic factors associated with high-risk patients will assist in 
patient management and potentially improved outcomes.
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Introduction
There is an increasing burden of pulmonary hypertension around the world. A recent global review 
 postulates that approximately 1% of the global population is affected [1]. In addition, approximately one-
tenth of those aged 65 years of age and above are thought to suffer pulmonary hypertension [1]. It is, 
however, important to note that PH increasingly affects people of all ages both in high-income and low to 
middle-income countries. Indeed, 80% of the burden of PH is felt in low and middle-income countries [1]. 
In Kenya, the prevalence of PH has only been studied in selected patient populations with specific diseases 
and it ranges between 5.5% and 49.4% [2, 3].
Pulmonary hypertension has various aetiologies [4]. This results in variation in the clinical profile of PH 
between patients and across different regions of the world [5, 6]. The prognosis of PH patients is dependent of 
different factors, and similar to the clinical profiles, they vary greatly [7]. Previous studies have demonstrated 
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that diseases and risk factors associated with PH in low and middle-income countries are highly prevalent in 
Kenya. These include: HIV, rheumatic heart disease, sickle cell disease and schistosomiasis [8, 9]. The perva-
sion of poor lifestyle choices and habits in Kenya, as well as in many other low and middle-income countries, 
means that the prevalence of hypertensive heart disease and chronic obstructive pulmonary disease is on 
the rise [10]. It then follows that there is more likely than not an increased risk of PH in Kenya that needs to 
be fully investigated.
Studies show that PH-related mortality rates are high, with associated low survival rates, especially for 
those with moderate to severe PH. A study of the the Registry to Evaluate Early and Long-term PAH Disease 
Management (REVEAL) in the United States found a 5 year-survival rate of 27% among patients with PH 
[11]. A study done in four countries in sub-Saharan Africa reported a 6-month mortality rate of 21% [5]. 
However, the long-term outcomes of African patients with PH have not been studied. In addition, the high 
PH mortality points to a need to understand and characterize prognostic factors associated with mortality or 
survival to better inform prevention and management efforts. This study, therefore, sought to determine the 
1-year and 3-year survival rates and prognostic factors associated with all-cause mortality among patients 
with moderate to severe PH attending a tertiary referral hospital in Kenya.
Methods
Study Design
This was a retrospective hospital-based cohort study of patients diagnosed with moderate to severe PH 
between August 2014 and July 2017. The study was carried out at Aga Khan University Hospital, Nairobi 
(AKUHN), a private non-profit tertiary referral hospital serving patients from Eastern Africa.
The study population was drawn from the AKUHN echo database of patients with a first echocardiographic 
diagnosis of moderate to severe PH from August 2014 to July 2017. Case definition was based on pulmonary 
artery systolic pressure (PASP) as follows: 45–59 mm Hg (moderate) and ≥60 mm Hg (severe) [12, 13]. Cases 
with missing clinical variables of interest were excluded. Other exclusion criteria included pulmonary valve 
peak velocity above 3 m/s and acute elevation of pulmonary pressure due to acute pulmonary embolism or 
acute lung pathologies.
Data collection
Data was collected from patient medical records using EPI INFO software version 7.2.1.0. Clinical variables 
were obtained from the medical records. Etiology of PH was defined as the one assigned by the primary 
physician after review of the clinical data and investigations available. Unclear causes from the available data 
would deem the cause of PH as ‘unclassified’. A 12-lead electrocardiogram was analyzed for the presence 
of atrial fibrillation based on American Heart Association (AHA) and Heart Rhythm Society guidelines [14].
Echocardiographic studies were performed using the GE Vivid 7 Dimension and Vivid Q Ultrasound 
machines utilizing a 3–5 MHz sector array transducer probe. Standard parasternal, apical and subcostal 
views were obtained. 2D-echocardiography, M-mode, and Doppler studies were performed on all patients. 
All echocardiograms were reviewed and validated by a certified consultant cardiologist.
Echocardiographic variables were defined according to the American Society of Echocardiography (ASE) 
guidelines [15, 16]. A simplified Bernoulli equation was used to estimate the PASP using the tricuspid regur-
gitant velocity (TRV) and right atrial pressures. Right atrial pressures were estimated by the use of size and 
extent of collapsibility of the inferior vena cava (IVC). Tricuspid annular plane systolic excursion (TAPSE) 
was used to assess RV function; it was measured by M-mode echocardiography with the cursor favorably 
positioned with the direction of the tricuspid lateral annulus in the apical four-chamber view. RV dysfunc-
tion was defined as TAPSE < 17 mm. The left ventricular ejection fraction was estimated using the Simpson 
method. Color flow Doppler allowed for the detection and grading severity of regurgitant lesions. Doppler 
measurements to determine gradients across valves were used to assess the severity of stenotic lesions. 
Significant valvular heart disease was defined as any moderate to severe stenosis or regurgitation. The pres-
ence of rheumatic valvular changes was captured by assessing valve morphology on 2D echocardiography. 
Telephone interviews were conducted when survival status was unknown from medical records. Patients 
were called directly at least two times, and if unsuccessful, the next of kin was contacted to provide outcome 
data. Where unavailable, censoring was done at the last date of hospital contact.
Data Analysis
Data analysis was carried out using SPSS version 24. Frequencies and proportions were used to summa-
rise categorical data, with bivariate relationships analysed using Pearson’s Chi-square. For continuous data 
means and standard deviations or medians and interquartile ranges were provided depending on the nor-
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mality of the data. Comparison of means and medians was done using t-tests and Mann-Whitney U tests, 
respectively.
Kaplan-Meier estimates were used in analysis of survival rates. The date of the first echocardiogram with 
PASP ≥ 45 mmHg was taken as the start date. Patients still alive at the end of the follow-up period or lost 
to follow-up were censored. Duration of follow up was calculated from the time of first echocardiographic 
diagnosis of PH to death or date of censoring. Reverse Kaplan-Meier method was utilized in calculation of 
the median follow-up time. Kaplan-Meier analysis method was used in the analysis of the survival rates and 
survival curve differences through the log-rank test.
Cox proportional hazard regression was modelled to capture the factors that were correlated with mortal-
ity among patients with moderate to severe PH. First, unadjusted Hazard Ratios were analysed by the use 
of univariate cox regression. Variables significant at p < 0.05 at this stage were analysed together using 
multivariate Cox regression to estimate adjusted Hazard Ratios with 95% confidence intervals. A two-tailed 
p < 0.05 was considered significant. 
Ethical Considerations
The study received approval from the Aga Khan University Ethics Review Committee. Respondents gave 
verbal consent over the telephone after the study and its aims were explained to them. Study data was 
anonymised and stored as per institutional policies to ensure confidentiality. The study protocol conforms to 
the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a prior approval by the institution’s 
human research committee.
Results
Study Cohort
A total of 8631 echocardiograms were carried out from August 2014 to July 2017 and 926 patients were 
found to have PASP ≥ 45 mmHg, of whom 267 patients did not meet the inclusion criteria, resulting in a 
cohort of 659 patients who were included in the final analysis as shown in Figure 1.
Figure 1: Flow diagram showing the selection of study cohort.
* Cases with absent clinical data or electrocardiogram.
** Patients with transient elevated PASP due to acute respiratory infections, acute respiratory distress 
 syndrome and positive pressure mechanical ventilation.
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Demographic and Clinical characteristics
The average age of respondents was 66 years (SD = 17.45), and majority were female (55.1%) and of black 
African race (80%). The most common comorbidity was systemic arterial hypertension (69.7%) followed 
by heart failure (52.2%). HIV was tested in 206 patients, of whom 28 (13.6%) were positive. Fifty-seven 
percent of the cohort were in functional class III or IV. Table 1 provides the summary of baseline patient 
 characteristics.
Echocardiographic and Electrocardiographic Findings
On electrocardiogram, 99 (15%) patients had atrial fibrillation. The median PASP was 56 mmHg (25th–75th 
percentiles: 49–68 mmHg) and TAPSE was 18 mm (25th–75th percentiles: 15–20 mm). About 28.2% of 
patients had LV ejection fraction below 40%, while 28.7% had significant valvular abnormalities. Surpris-
Table 1: Baseline Demographic and Clinical Characteristics.
All patients
N = 659
Demographics
Age (years) 65.72 ± 17.45
Gender, n (%)
Females 363 (55.1)
Males 296 (44.9)
Race
Blacks, n (%) 527 (80.0)
Non-Blacks, n (%) 132 (20.0)
Comorbidities
Systemic Arterial Hypertension, n (%) 459 (69.7)
Diabetes Mellitus, n (%) 224 (34.0)
Smoking, n (%) 66 (10.0)
Heart failure, n (%) 344 (52.2)
COPD, n (%) 78 (11.8)
HIV, n (%) N = 206 28 (13.6)
Systolic BP (mmHg), median (IQR) 82 (72–94)
Systolic BP (mmHg), median (IQR) 129 (111–147)
Weight (kg) 76.23 ± 18.82
Body Mass Index, median (IQR) 28 (24–32)
Underweight, BMI < 18.5 22 (3.3%)
Normal, BMI 18.5–24.9 161 (24.4%)
Overweight, BMI 25.0–29.9 235 (35.7%)
Stage I obesity, BMI 30.0–34.9 136 (20.6%)
Stage II obesity, BMI 35.0–39.9 59 (9%)
Extreme Obesity, BMI ≥ 40.0 43 (6.5%)
WHO functional class, n (%)
Class I/II 192 (43.5)
Class III/V 249 (56.5)
* Plus-minus values are means ± SD.
IQR, interquartile range; COPD, chronic obstructive pulmonary disease; HIV, human immunodeficiency virus; BP, blood 
pressure; WHO, world health organization.
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ingly, rheumatic and congenital heart diseases were present in similar proportions (5.6% vs. 5.8%). The 
summary of the other findings is shown in Table 2.
Aetiologies of PH
Figure 2 below shows the classification of PH as assigned by the patient’s primary physician (n = 546). There 
was no cause assigned to 113 patients (17%). From the chart, it can be seen that the most common aetiol-
ogy of PH in this cohort was PH due to left heart disease (58%), followed by PH due to lung disease (22%), 
pulmonary arterial hypertension (13%) and chronic thromboembolic pulmonary hypertension (5%). 
Table 2: Electrocardiographic and Echocardiographic findings.
All patients
(N = 650)
Electrocardiographic findings
Atrial Fibrillation, n (%) 99 (15.0)
Echocardiographic findings
TRV (ms), median (IQR) 3.42 (3.22–3.79)
RAP (mmHg) 9.60 ± 5.28
PASP (mmHg), median (IQR) 56 (49–68)
TAPSE (mm) (N = 580), median (IQR) 18 (15–20)
LVEF (%), median (IQR) 55 (38–60)
LVEF < 40%  186 (28.2)
Congenital Heart Disease, n (%) 38 (5.8)
Significant valvular abnormalities, n (%)  189 (28.7)
Rheumatic valvular changes, n (%) 37 (5.6)
* Plus-minus values are means ± SD.
IQR, interquartile range; TRV, tricuspid regurgitant velocity; RAP, right atrial pressure; PASP, pulmonary artery systolic 
pressure; TAPSE, tricuspid annular plane systolic excursion; LVEF, left ventricular ejection fraction.
Figure 2: WHO groups of pulmonary hypertension assigned by primary physician.
PAH: pulmonary arterial hypertension; PH-LHD: PH due to left heart disease; PH-LD: PH due to lung disease; 
CTEPH: chronic thromboembolic PH.
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In terms of sub-groups, congenital heart disease (n = 31, 5.7%) was the most common cause of PAH, fol-
lowed by HIV-associated PAH (n = 18, 3.3%). Heart failure with reduced ejection fraction was the most com-
mon cause of PH due to left heart disease (n = 164, 30%). Rheumatic heart disease was a cause of PH in 6.6% 
of patients. Among those with PH caused by lung disease (PH-LD), chronic obstructive pulmonary disease 
was the most frequent cause (n = 63, 11.5%), followed by sleep-disordered breathing (n = 23, 4.2%). Table 3 
provides a detailed description of the sub-group classification.
Follow-up and Outcomes
By the end of the study period (median follow-up time: 626 days), 198 patients (30%) had died. As shown in 
Table 4, the overall survival at 6 months, 1 and 2 years of follow-up was 78.9%, 73.8% and 65.9% respec-
tively. Kaplan-Meier survival curves for the entire cohort by WHO functional class, obesity, PASP, left ventricu-
lar dysfunction and right ventricular dysfunction are shown in Figure 3. 
There were statistically significant differences in survival between the 2 groups. The deceased group 
reported significantly higher PASP, WHO functional class, left ventricular systolic and right ventricular dys-
function (log-rank test p = < 0.001). The estimated survival rates of the PH patients with WHO FC III/IV at 6 
months, 1 and 2 years were 54%, 47% and 41% respectively. Patients who were obese (BMI ≥ 30kg/m2) at 
the time of diagnosis had a better overall survival (log rank test P = 0.01).
Table 3: Sub-group classification of pulmonary hypertension.
Total
(N = 546)
%
Group 1 72
Congenital heart disease 31 5.7%
HIV associated PAH 18 3.3%
Connective tissue disease 15 2.7%
Idiopathic PAH 6 1.1%
Portal hypertension 2 0.4%
Group 2 318
HFrEF 164 30.0%
HFpEF 85 15.6%
Rheumatic valvular heart disease 36 6.6%
Other valvular heart diseases 31 5.6%
Others 2 0.4%
Group 3 122
COPD 63 11.5%
Sleep disordered breathing 23 4.2%
Interstitial lung disease 13 2.4%
Post TB bronchiectasis 7 1.3%
Others 14 2.89%
Group 4 28 5.1%
Group 5 8
Sickle cell disease 4 0.7%
Others 4 0.7%
PAH, pulmonary arterial hypertension; HFrEF, heart failure with reduced ejection fraction; COPD, chronic obstructive 
pulmonary disease; HFpEF, heart failure with preserved ejection fraction; TB, tuberculosis. Of the congenital heart 
disease 16 had ASD, 1 PDA, 1 VSD, 4 Tetralogy of Fallot and 9 others.
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Table 4: Two-year survival rates.
Probability of survival (%)
6 months 78.9 ± 1.6
1 year 73.8 ± 1.8
2 years 65.9 ± 2.1
* Plus-minus values are overall survival rate ± SE.
Figure 3: Kaplan-Meier survival estimates for (A) Overall cohort; (B) by WHO functional class; (C) by BMI; 
(D) by severity of PASP; (E) by LVEF and (F) by TAPSE.
WHO, World Health Organization; BMI, Body Mass Index; PH, pulmonary hypertension; PASP, pulmonary 
artery systolic pressures; LVEF, left ventricular ejection fraction; LV, left ventricular; RV, right ventricular; 
TAPSE, tricuspid annular plane systolic excursion.
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Prognostic Factors Associated with Mortality
The relationship between mortality and prognostic factors was assessed in a univariate cox regression 
model. All factors were prognostic except gender, systemic arterial hypertension and rheumatic heart dis-
ease. Upon testing in a multivariate cox regression model, significant valvular heart disease lost its prog-
nostic value. However, age [adjusted HR 1.02, 95% CI (1.01–1.03)], diabetes mellitus [adjusted HR 1.49, 
95% CI (1.13–1.98)], WHO functional class III/IV [adjusted HR 3.50, 95% CI (2.47–4.97)], atrial fibrillation 
[adjusted HR 1.53, 95% CI (1.07–2.17)], severe PH [adjusted HR 1.68, 95% CI (1.27–2.22)], right ventricular 
dysfunction [adjusted HR 2.61, 95% CI (1.93–3.53)] and left ventricular dysfunction [adjusted HR 2.18, 95% 
CI (1.64–2.91)] were still independently associated with mortality. Obesity was paradoxically associated with 
improved survival [adjusted HR 0.68, 95% CI (0.50–0.93)]. The results of the cox regression are shown in 
Table 5.
Discussion
Knowledge about PH in sub-Saharan Africa is largely drawn from the PAPUCO study [5]. The study was pro-
spective and included participants of different ethnic groups from four African countries (i.e. Cameroon, 
Nigeria, Mozambique and South Africa) [5]. In this study, a diagnosis of PH was made on the basis of echo-
cardiography—right ventricular systolic pressure >35 mmHg, the absence of pulmonary stenosis and acute 
right ventricular failure, although the exact definitions of these exclusion criteria variables used in the study 
were not mentioned in the study protocol [17]. The registry data published in June 2016 examined the clini-
cal profiles, aetiologies and six-month outcomes of patients with PH [5]. However, the prognostic factors 
of mortality and long-term survival have not been comprehensively examined. Therefore, the present study 
sought to determine the long-term outcomes and associated factors in a cohort with moderate to severe 
PH. This retrospective cohort study represents one of the largest studies on pulmonary hypertension (PH) in 
sub-Saharan Africa (SSA).
The study cohort comprised more females than males, similar to what has been reported in other studies 
[5]. This may be attributable to the fact that certain aetiologies of PH, such as PAH and rheumatic heart dis-
ease, have a strong bias towards females [18, 19]. Compared to the PAPUCO study, median age in this group 
was 18 years higher. This can be explained by the high prevalence of left heart disease in this study, which is 
highly prevalent among the elderly [1, 5]. The majority of the patients were diagnosed late, as illustrated by 
Table 5: Cox regression analysis.
Univariate Analysis¶ Multivariate Analysis¥
Unadjusted HR ± 95% CI p-value Adjusted HR ± 95% CI p-value
Age 1.03 (1.02–1.04) <0.001 1.02 (1.01–1.03) <0.001
Male Gender 1.23 (0.93–1.63) 0.14 1.17 (0.88–1.54) 0.29
Systemic Arterial Hypertension 1.12 (0.82–1.54) 0.50 0.73 (0.52–1.02) 0.07
Diabetes Mellitus 1.61 (1.22–2.14) 0.001 1.49 (1.13–1.98) 0.005
Obesity (BMI ≥ 30) 0.68 (0.50–0.93) 0.01 0.66 (0.48–0.90) 0.01
WHO Class III/IV 3.53 (2.49–5.00) <0.001 3.50 (2.47–4.97) <0.001
Atrial Fibrillation 1.72 (1.22–2.42) 0.001 1.53 (1.07–2.17) 0.02
Severe PH (PASP ≥ 60) 1.68 (1.27–2.22) <0.001 1.68 (1.27–2.22) <0.001
RV dysfunction (TAPSE < 17 mm) 2.58 (1.92–3.48) <0.001 2.61 (1.93–3.53) <0.001
LV dysfunction (LVEF ≤ 40%) 2.15 (1.62–2.85) <0.001 2.18 (1.64–2.91) <0.001
Significant valvular heart disease 1.44 (1.07–1.93) 0.02 1.28 (0.93–1.76) 0.13
Rheumatic heart disease 0.54 (0.24–1.21) 0.13 1.19 (0.50–2.80) 0.70
¶ Cox regression performed after confirmation of proportional hazard assumptions using log minus log graphs. 
¥ A multivariate cox regression model adjusted for confounders (age, gender, race and presence of diabetes mellitus).
* P < 0.05 was considered significant. 
BMI, body mass index; WHO, world health organization; PH, pulmonary hypertension; RV, right ventricle; LV, left 
 ventricle; TAPSE, tricuspid annular plane systolic excursion; LVEF, left ventricular ejection fraction.
Interactions for Obesity and Age, Obesity and DM, and Obesity and Gender were performed and no interactions were 
present.
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the high proportion of those in WHO functional class III and IV. This finding is consistent with other African 
studies on PH [5, 20]. In the PAPUCO study, Thienemann et al. reported that two-thirds of patients with PH 
presented in WHO class III/IV [5]. This may be due to low access to care, healthcare worker education gaps 
or lack of diagnostic capacity, given low resources [5].
Similar to other studies, PH due to left heart disease (PH-LHD) was the most common, accounting for 30% 
in this cohort, though at a lower prevalence than the 69% reported in previous studies [5]. This is because 
our study had a higher prevalence of PH due to lung disease and CTEPH. PH-LHD was majorly attributed to 
heart failure characterised by reduced ejection fraction, consistent with studies demonstrating high occur-
rence of systolic heart failure in Africa [21]. It was disconcerting to note that rheumatic valvular disease was 
also associated with PH in this study, pointing to its endemicity and contribution to the cardiovascular dis-
ease burden in this setting. Contrary to other studies, tuberculosis-associated obstructive pulmonary disease 
was not a significant cause of PH-LD [5, 20]. This may be due to mis-classification, since not all patients were 
evaluated systematically to exclude tuberculosis.
In terms of survival, the findings are similar to those of the PAPUCO study that reported a high rate of 
mortality at 6 months follow-up [5]. Nonetheless, the overall 3-year survival in this group of patients is 5 to 
10% lower than those reported in studies outside Africa [6, 22–23]. This may be attributed to the exclusion 
of patients with mild PH in this study, as well as the barriers to early diagnosis and treatment of PH in this 
setting [5].
Age was one of the prognostic factors for PH mortality. Older age has been shown to place PH patients at 
an increased risk of mortality [6, 22]. The Giessen Pulmonary Hypertension registry demonstrated that age 
<50 years predicted survival in all PH groups [22]. A separate study showed that individuals aged ≥65 yrs 
have high mortality rates [24]. Though systemic arterial hypertension was highly prevalent in our cohort, it 
had no significant influence on mortality. This is consistent with findings from other heart failure studies 
in Africa [21].
Several clinical variables were associated with mortality similar to other studies. These included poor func-
tional class (WHO functional class III/IV), diabetes mellitus and atrial fibrillation [6, 22, 24, 25].
The observed reduced mortality in obese patients may support the ‘obesity paradox’ hypothesis. This 
finding is consistent with that of Zafrir et al., who found that obesity was significantly associated with 
lower mortality in PH patients (HR 0.2, 95% CI 0.1–0.6; P = 0.004) [26]. In another study, Caceres et al. 
observed that a higher BMI was associated with a lower relative risk for one year mortality in patients 
with PH [27]. The ‘obesity paradox’ in this cohort may indeed be due to the effect of higher muscle mass 
in this cohort of patients rather than the BMI, a finding that was not explored, but has been found in 
other trials [28]. Recent studies have, however, disputed this. A large population-based study revealed 
that obesity is associated with shorter longevity and significantly higher cardiovascular risk compared to 
normal weight [29]. A possible explanation for this conflicting data may be the presence of significant 
confounding from prevalent disease-related weight loss in studies showing the ‘obesity paradox’ phe-
nomenon [30].
Echocardiographic parameters identified to be independently associated with mortality in PH were PASP, 
TAPSE and left ventricular ejection fraction. Various studies have demonstrated the link between PH severity 
and mortality [6, 25]. In the Armadale cohort, a higher PASP (>60 mmHg) conferred a 3.29 higher odds of 
mortality compared to patients with lower PASP [6]. Corciova et al. revealed a strong association between 
PASP and survival duration (r 0.52, p < 0.001) [25]. Right ventricular dysfunction has been related with poor 
outcomes in PH [25, 31]. Using lower cut-off of less than 17 mm, unlike these authors who used a TAPSE cut-
off of 18 mm, we also observed a higher risk of mortality. Similar to Corciova et al., left ventricular systolic 
dysfunction (LVEF ≤ 40%) was a prognostic factor for mortality [25]. This is attributed to the fact that more 
than half of patients had PH-LHD [25].
Limitations
Several limitations of this study need to be acknowledged. The diagnosis of PH was based on echo-derived 
PASP and not right heart catheterization as recommended. The other important limitation lies in the fact 
that the aetiologies were entirely based on what was assigned by the primary physician, abstracted from the 
patients’ medical records. The heterogeneity of our patients was another limitation of the study. Our sample 
size limited our capacity to do a detailed analysis of each aetiology. Future studies should target specific 
aetiologies of PH in the region. Lastly, the generalized application of these findings is subject to certain 
limitations. This was a single-centre study in an urban setting. In the future, it will be important to do a 
multicentre study that will include health facilities in rural areas as well.
Ngunga et al: Long-Term Outcomes and Factors Associated with Mortality in Patients with 
Moderate to Severe Pulmonary Hypertension in Kenya
Art. 6, page 10 of 12
Conclusion
The study findings clearly indicate that PH is associated with high mortality in African patients. Only about 
66% of the patients were alive after two years from the time of diagnosis. Increased mortality risk was associ-
ated with diabetes mellitus, atrial fibrillation, WHO FC III/IV, severe PH (PASP ≥ 60 mmHg), right ventricular 
dysfunction (TAPSE < 17 mm) and left ventricular systolic dysfunction (LVEF ≤ 40%). Obesity was associated 
with improved survival. On the other hand, the presence of rheumatic heart disease or significant valvular 
abnormalities had no effect on mortality.
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